Analysis of the differential effects of Interferon-alpha (IFN-α) on myeloma cell proliferation

Taruna Arora, Diane F Jelinek

Research output: Contribution to journalArticle

Abstract

IFN-α is a commonly used chemotherapeutjc agent for the treatment of multiple myeloma. The effectiveness of IFN-a in vivo is variable, as is its anti-proliferative effects on cultured myeloma cells. The mechanism(s) accounting for this variability is not yet understood. In these studies, we have utilized two interleukin 6 (IL-6) dependent human myeloma cell lines, ANBL-6 and KAS-6/1, which are differentially regulated by IFN-a. Thus, IFN-a potently inhibits ANBL-6 growth whereas it supports significant growth by the KAS-6/1 cells. To understand these differences, we have analyzed IFN-a induced modifications in cell cycle regulatory proteins. Initial studies examined the effects of IL-6 and IFN-a on phosphorylation of the retinoblastoma protein (RB). Kinetic studies in ANBL-6 and KAS-6/1 cells revealed that a 12 hr incubation with IL-6 resulted in RB inactivation, i.e. hyperphosphorylation, in both cell lines. By contrast, IFN-a only induced RB hyperphosphorylation in the KAS-6/1 cells and was further noted to inhibit IL-6 stimulated RB hyperphosphorylation in the ANBL-6 cells. We next analyzed cell cycle molecules that lie upstream of RB. Similar studies were performed examining the effects of IFN-a on induction of cyclin D expression and CDK2/CDK4 activity. Again, IFN-a stimulation of the KAS6/1 cells increased cyclin D expression and CDK2 activity whereas IFN-a treatment of ANBL-6 cells +/- IL-6 inhibited both proteins. IFN-a , however had no effect on basal levels of CDK4 activity. These data suggest that IFN-a inhibits or stimulates myeloma cell growth by altering the functional interactions between the cyclin D-CDK2 complex and RB. Because these interactions occur in the nucleus, it is likely that the signals accounting for the differential ability of IFN-a to support myeloma cell growth lie upstream of nuclear events.

Original languageEnglish (US)
JournalFASEB Journal
Volume10
Issue number6
StatePublished - 1996

Fingerprint

interferon-alpha
myeloma
Cell proliferation
Interferon-alpha
cell proliferation
Cell Proliferation
Retinoblastoma Protein
interleukin-6
Interleukin-6
Cyclin D
cyclins
cells
proteins
Cells
Cell growth
Growth
cell growth
cell cycle
cell lines
Cyclin-Dependent Kinase 2

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Analysis of the differential effects of Interferon-alpha (IFN-α) on myeloma cell proliferation. / Arora, Taruna; Jelinek, Diane F.

In: FASEB Journal, Vol. 10, No. 6, 1996.

Research output: Contribution to journalArticle

@article{50982bd6f7f940a4b054e67b663e06eb,
title = "Analysis of the differential effects of Interferon-alpha (IFN-α) on myeloma cell proliferation",
abstract = "IFN-α is a commonly used chemotherapeutjc agent for the treatment of multiple myeloma. The effectiveness of IFN-a in vivo is variable, as is its anti-proliferative effects on cultured myeloma cells. The mechanism(s) accounting for this variability is not yet understood. In these studies, we have utilized two interleukin 6 (IL-6) dependent human myeloma cell lines, ANBL-6 and KAS-6/1, which are differentially regulated by IFN-a. Thus, IFN-a potently inhibits ANBL-6 growth whereas it supports significant growth by the KAS-6/1 cells. To understand these differences, we have analyzed IFN-a induced modifications in cell cycle regulatory proteins. Initial studies examined the effects of IL-6 and IFN-a on phosphorylation of the retinoblastoma protein (RB). Kinetic studies in ANBL-6 and KAS-6/1 cells revealed that a 12 hr incubation with IL-6 resulted in RB inactivation, i.e. hyperphosphorylation, in both cell lines. By contrast, IFN-a only induced RB hyperphosphorylation in the KAS-6/1 cells and was further noted to inhibit IL-6 stimulated RB hyperphosphorylation in the ANBL-6 cells. We next analyzed cell cycle molecules that lie upstream of RB. Similar studies were performed examining the effects of IFN-a on induction of cyclin D expression and CDK2/CDK4 activity. Again, IFN-a stimulation of the KAS6/1 cells increased cyclin D expression and CDK2 activity whereas IFN-a treatment of ANBL-6 cells +/- IL-6 inhibited both proteins. IFN-a , however had no effect on basal levels of CDK4 activity. These data suggest that IFN-a inhibits or stimulates myeloma cell growth by altering the functional interactions between the cyclin D-CDK2 complex and RB. Because these interactions occur in the nucleus, it is likely that the signals accounting for the differential ability of IFN-a to support myeloma cell growth lie upstream of nuclear events.",
author = "Taruna Arora and Jelinek, {Diane F}",
year = "1996",
language = "English (US)",
volume = "10",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "6",

}

TY - JOUR

T1 - Analysis of the differential effects of Interferon-alpha (IFN-α) on myeloma cell proliferation

AU - Arora, Taruna

AU - Jelinek, Diane F

PY - 1996

Y1 - 1996

N2 - IFN-α is a commonly used chemotherapeutjc agent for the treatment of multiple myeloma. The effectiveness of IFN-a in vivo is variable, as is its anti-proliferative effects on cultured myeloma cells. The mechanism(s) accounting for this variability is not yet understood. In these studies, we have utilized two interleukin 6 (IL-6) dependent human myeloma cell lines, ANBL-6 and KAS-6/1, which are differentially regulated by IFN-a. Thus, IFN-a potently inhibits ANBL-6 growth whereas it supports significant growth by the KAS-6/1 cells. To understand these differences, we have analyzed IFN-a induced modifications in cell cycle regulatory proteins. Initial studies examined the effects of IL-6 and IFN-a on phosphorylation of the retinoblastoma protein (RB). Kinetic studies in ANBL-6 and KAS-6/1 cells revealed that a 12 hr incubation with IL-6 resulted in RB inactivation, i.e. hyperphosphorylation, in both cell lines. By contrast, IFN-a only induced RB hyperphosphorylation in the KAS-6/1 cells and was further noted to inhibit IL-6 stimulated RB hyperphosphorylation in the ANBL-6 cells. We next analyzed cell cycle molecules that lie upstream of RB. Similar studies were performed examining the effects of IFN-a on induction of cyclin D expression and CDK2/CDK4 activity. Again, IFN-a stimulation of the KAS6/1 cells increased cyclin D expression and CDK2 activity whereas IFN-a treatment of ANBL-6 cells +/- IL-6 inhibited both proteins. IFN-a , however had no effect on basal levels of CDK4 activity. These data suggest that IFN-a inhibits or stimulates myeloma cell growth by altering the functional interactions between the cyclin D-CDK2 complex and RB. Because these interactions occur in the nucleus, it is likely that the signals accounting for the differential ability of IFN-a to support myeloma cell growth lie upstream of nuclear events.

AB - IFN-α is a commonly used chemotherapeutjc agent for the treatment of multiple myeloma. The effectiveness of IFN-a in vivo is variable, as is its anti-proliferative effects on cultured myeloma cells. The mechanism(s) accounting for this variability is not yet understood. In these studies, we have utilized two interleukin 6 (IL-6) dependent human myeloma cell lines, ANBL-6 and KAS-6/1, which are differentially regulated by IFN-a. Thus, IFN-a potently inhibits ANBL-6 growth whereas it supports significant growth by the KAS-6/1 cells. To understand these differences, we have analyzed IFN-a induced modifications in cell cycle regulatory proteins. Initial studies examined the effects of IL-6 and IFN-a on phosphorylation of the retinoblastoma protein (RB). Kinetic studies in ANBL-6 and KAS-6/1 cells revealed that a 12 hr incubation with IL-6 resulted in RB inactivation, i.e. hyperphosphorylation, in both cell lines. By contrast, IFN-a only induced RB hyperphosphorylation in the KAS-6/1 cells and was further noted to inhibit IL-6 stimulated RB hyperphosphorylation in the ANBL-6 cells. We next analyzed cell cycle molecules that lie upstream of RB. Similar studies were performed examining the effects of IFN-a on induction of cyclin D expression and CDK2/CDK4 activity. Again, IFN-a stimulation of the KAS6/1 cells increased cyclin D expression and CDK2 activity whereas IFN-a treatment of ANBL-6 cells +/- IL-6 inhibited both proteins. IFN-a , however had no effect on basal levels of CDK4 activity. These data suggest that IFN-a inhibits or stimulates myeloma cell growth by altering the functional interactions between the cyclin D-CDK2 complex and RB. Because these interactions occur in the nucleus, it is likely that the signals accounting for the differential ability of IFN-a to support myeloma cell growth lie upstream of nuclear events.

UR - http://www.scopus.com/inward/record.url?scp=33749128746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749128746&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 6

ER -